Antares Pharma (AIS) Enters License Agreement with Pfizer's (PFE) Consumer Healthcare Unit

Antares Pharma, Inc. (AMEX: AIS) has licensed to Pfizer Inc.’s (NYSE: PFE) Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer will assume full cost and responsibility for all clinical development, manufacturing, and commercialization of the product in the licensed territory, which also includes certain non-exclusive territories outside of North America. Antares will receive undisclosed upfront payments, development milestones and sales based milestones, as well as royalties on net sales for three years post launch in the US.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
• Sony (SNE) Said to Pay for 3-D Glasses for 'Men In Black 3' -Bloomberg (RLD)
• Mylan Inc. (MYL) Settles Patent Litigation with Sunovion Pharmaceuticals

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter